Format

Send to

Choose Destination
J Thorac Cardiovasc Surg. 2015 Oct;150(4):796-803.e1-2. doi: 10.1016/j.jtcvs.2015.08.001. Epub 2015 Aug 6.

Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer.

Author information

1
Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Wash; Surgical Outcomes Research Center, University of Washington, Seattle, Wash. Electronic address: ffarjah@uw.edu.
2
Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Wash; Division of Pulmonary and Critical Care Medicine, Fred Hutchinson Cancer Research Center, Seattle, Wash.
3
Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Wash.
4
Surgical Outcomes Research Center, University of Washington, Seattle, Wash.
5
Center for Lung Biology, University of Washington, Seattle, Wash.
6
Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Wash; Center for Lung Biology, University of Washington, Seattle, Wash.

Abstract

OBJECTIVE:

Vascular endothelial growth factors (VEGFs) C and D are biologically rational markers of nodal disease that could improve the accuracy of lung cancer staging. We hypothesized that these biomarkers would improve the ability of positron emission tomography (PET) to predict nodal disease among patients with suspected or confirmed non-small cell lung cancer (NSCLC).

METHODS:

A cross-sectional study (2010-2013) was performed of patients prospectively enrolled in a lung nodule biorepository, staged by computed tomography (CT) and PET, and who underwent pathologic nodal evaluation. Enzyme-linked immunosorbent assay was used to measure biomarker levels in plasma from blood drawn before anesthesia. Likelihood ratio testing was used to compare the following logistic regression prediction models: ModelPET, ModelPET/VEGF-C, ModelPET/VEGF-D, and ModelPET/VEGF-C/VEGF-D. To account for 5 planned pairwise comparisons, P values <.01 were considered significant.

RESULTS:

Among 62 patients (median age, 67 years; 48% men; 87% white; and 84% NSCLC), 58% had fluorodeoxyglucose uptake in hilar and/or mediastinal lymph nodes. The prevalence of pathologically confirmed lymph node metastases was 40%. Comparisons of prediction models revealed the following: ModelPET/VEGF-C versus ModelPET (P = .0069), ModelPET/VEGF-D versus ModelPET (P = .1886), ModelPET/VEGF-C/VEGF-D versus ModelPET (P = .0146), ModelPET/VEGF-C/VEGF-D versus ModelPET/VEGF-C (P = .2818), and ModelPET/VEGF-C/VEGF-D versus ModelPET/VEGF-D (P = .0095). In ModelPET/VEGF-C, higher VEGF-C levels were associated with an increased risk of nodal disease (odds ratio, 2.96; 95% confidence interval, 1.26-6.90).

CONCLUSIONS:

Plasma levels of VEGF-C complemented the ability of PET to predict nodal disease among patients with suspected or confirmed NSCLC. VEGF-D did not improve prediction.

KEYWORDS:

biomarkers; diagnostic test; lung cancer; prediction models; risk prediction

Comment in

PMID:
26320776
PMCID:
PMC4889434
DOI:
10.1016/j.jtcvs.2015.08.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center